This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Morgan, M. A. Articles by Lawrence, T. S. PubMed PubMed Citation Articles by Morgan, M. A. Articles by Lawrence, T. S.

The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer

Authors' Affiliations: Departments of ¹ Radiation Oncology and ² Pharmacology, University of Michigan, Ann Arbor, Michigan

Requests for reprints: Meredith A. Morgan, Department of Radiation Oncology, University of Michigan Medical Center, 1301 Catherine Street, Room 43264A, Medical Sciences I, Ann Arbor, MI 48109-5637. Phone: 734-647-5928; Fax: 734-763-1581; E-mail: mmccrack{at}med.umich.edu.

Purpose: Gemcitabine-radiotherapy is a standard treatment for locally advanced pancreatic cancer. Clinical data have shown that gemcitabine plus erlotinib is superior to gemcitabine alone for advanced pancreatic cancer. Therefore, we investigated the effects of the combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation on a pancreatic cancer model.

Experimental Design: EGFR signaling was analyzed by measuring phosphorylated EGFR (pEGFR^{(Y845), (Y1173)}) and AKT (pAKT^(S473)) protein levels in pancreatic cancer cell lines and tumors. The effects of scheduling on gemcitabine-mediated cytotoxicity and radiosensitization combined with erlotinib were determined by clonogenic survival. In vivo, the effects of cetuximab or erlotinib in combination with gemcitabine-radiation on the growth of BxPC-3 tumor xenografts were measured.

Results: We found in vitro that gemcitabine induced phosphorylation of EGFR at Y845 and Y1173 that was blocked by erlotinib. Treatment of BxPC-3 cells with gemcitabine before erlotinib enhanced gemcitabine-mediated cytotoxicity without abrogating radiosensitization. In vivo, cetuximab or erlotinib in combination with gemcitabine-radiation inhibited growth compared with gemcitabine-radiation (time to tumor doubling: gemcitabine + radiation, 19 ± 3 days; cetuximab + gemcitabine + radiation, 30 ± 3 days; P < 0.05, erlotinib + gemcitabine + radiation 28 ± 3 days; P < 0.1). Cetuximab or erlotinib in combination with gemcitabine-radiation resulted in significant inhibition of pEGFR^(Y1173) and pAKT^(S473) early in treatment, and pEGFR^(Y845), pEGFR^(Y1173), and pAKT^(S473) by the end of treatment. This study shows a novel difference pEGFR^(Y845) and pEGFR^(Y1173) in response to EGFR inhibition.

Conclusions: These results show that the EGFR inhibitors cetuximab and erlotinib increase the efficacy of gemcitabine-radiation. This work supports the integration of EGFR inhibitors with gemcitabine-radiation in clinical trials for pancreatic cancer.

This article has been cited by other articles:

				M. A. Morgan, L. A. Parsels, J. Maybaum, and T. S. Lawrence Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review Clin. Cancer Res., November 1, 2008; 14(21): 6744 - 6750. [Abstract] [Full Text] [PDF]